Search by Drug Name or NDC
NDC 00002-7678-01 CYRAMZA 10 mg/mL Details
CYRAMZA 10 mg/mL
CYRAMZA is a INTRAVENOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is RAMUCIRUMAB.
MedlinePlus Drug Summary
Ramucirumab injection is used alone and in combination with another chemotherapy medication to treat stomach cancer or cancer located in the area where the stomach meets the esophagus (the tube between the throat and stomach) when these conditions do not improve after treatment with other medications. Ramucirumab is also used in combination with docetaxel to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body in people who have already been treated with other chemotherapy medications and have not improved or worsened. It is also used in combination with erlotinib (Tarceva) to a certain type of NSCLC that has spread to other parts of the body. Ramucirumab is also used in combination with other chemotherapy medications to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body in people that have already been treated with other chemotherapy medications and have not improved or worsened. Ramucirumab is also used alone to treat certain people with hepatocellular carcinoma (HCC; a type of liver cancer) who have already been treated with sorafenib (Nexafar). Ramucirumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.
Related Packages: 00002-7678-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ramucirumab Injection
Product Information
| NDC | 00002-7678 |
|---|---|
| Product ID | 0002-7678_7ba2dde4-bb6d-4c7b-af6a-361ed01bfdf6 |
| Associated GPIs | 21335070002040 |
| GCN Sequence Number | 072294 |
| GCN Sequence Number Description | ramucirumab VIAL 500MG/50ML INTRAVEN |
| HIC3 | V3P |
| HIC3 Description | ANTINEOPLASTIC - VEGFR ANTAGONIST |
| GCN | 36445 |
| HICL Sequence Number | 041109 |
| HICL Sequence Number Description | RAMUCIRUMAB |
| Brand/Generic | Brand |
| Proprietary Name | CYRAMZA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ramucirumab |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/mL |
| Substance Name | RAMUCIRUMAB |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | VEGFR2 Inhibitors [MoA], Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125477 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00002-7678-01 (00002767801)
| NDC Package Code | 0002-7678-01 |
|---|---|
| Billing NDC | 00002767801 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-7678-01) / 50 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2014-04-21 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |